<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03049410</url>
  </required_header>
  <id_info>
    <org_study_id>16/0584</org_study_id>
    <nct_id>NCT03049410</nct_id>
  </id_info>
  <brief_title>Trial to Compare Robotically Assisted Radical Cystectomy With Open Radical Cystectomy</brief_title>
  <acronym>iROC</acronym>
  <official_title>A Phase III Multicentre Randomised Controlled Trial to Compare the Efficacy of Robotically Assisted Radical Cystectomy (RARC) and Intracorporeal Urinary Diversion With Open Radical Cystectomy (ORC) in Patients With Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective multicentre randomised controlled trial comparing the outcomes from&#xD;
      Intracorporeal RARC (iRARC) with open radical cystectomy (ORC) in patients with bladder&#xD;
      cancer. The study will recruit patients with non-muscle invasive bladder cancer (NMIBC) or&#xD;
      muscle invasive bladder cancer (MIBC) who have selected radical cystectomy for the treatment&#xD;
      of bladder cancer. The time of interest for measurement of the primary outcomes will be 90&#xD;
      days post-surgery.&#xD;
&#xD;
      Eligible patients will include those receiving neo-adjuvant chemotherapy (typically&#xD;
      gemcitabine and cisplatin) and those having either an ileal conduit or a neo-bladder&#xD;
      reconstruction.&#xD;
&#xD;
      Patients who have selected radical cystectomy after appropriate counselling and following a&#xD;
      specialist multi-disciplinary team (SMDT) recommendation, will be approached and asked to&#xD;
      consent for this study.&#xD;
&#xD;
      Consenting participants will be randomised 1:1 to either iRARC or ORC. Patients will be&#xD;
      followed for a minimum of 90 days post-surgery.&#xD;
&#xD;
      The study will be conducted in National Health Service (NHS) Trusts designated as Cancer&#xD;
      Centres.&#xD;
&#xD;
      Patients will be stratified by&#xD;
&#xD;
        -  Type of urinary diversion (Continent diversion or ileal conduit)&#xD;
&#xD;
        -  Performance status&#xD;
&#xD;
        -  Centre Trial assessments will be conducted at baseline (before surgery), whilst&#xD;
           participants are on admission and then 5, 12, 26 weeks,1 year and 18 months post&#xD;
           surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radical cystectomy (RC) represents the gold standard treatment for invasive bladder cancer.&#xD;
      Reductions in morbidity and mortality from this operation have occurred in recent years&#xD;
      through refined anaesthesia, surgical techniques, and centralization of services in high&#xD;
      volume centres. The multimodal concept of enhanced recovery after RC (ERAS), which includes&#xD;
      pre, intra and post operative steps, has also helped to reduce the length of stay and&#xD;
      complications after RC further.&#xD;
&#xD;
      For most abdominal surgery, it is recognized that minimally invasive surgery is less morbid&#xD;
      than open surgery, and produces improvements in post-operative recovery without altering the&#xD;
      curative nature of the procedure. However, to date, there is little or conflicting evidence&#xD;
      of any benefit from minimally invasive surgery over open surgery for RC. This may reflect the&#xD;
      complex nature of this procedure (involving surgery to both the urinary and gastro-intestinal&#xD;
      tracts), limitations of the current evidence or that there is no benefit. To date, three&#xD;
      prospective trials have compared RARC with open RC (ORC). However, each has been limited by&#xD;
      sample size and design, or their application of RARC with extra-corporeal reconstruction or&#xD;
      have yet to report.&#xD;
&#xD;
      The investigators believe that there are no studies (reported or planned) that have compared&#xD;
      optimal RARC (e.g. with intra-corporeal reconstruction) with optimal ORC (e.g. high volume&#xD;
      centre using ERAS). In addition, the investigators believe none have adequately assessed the&#xD;
      rehabilitation from RC. As such, the investigators now propose a prospective RCT to randomize&#xD;
      eligible patients to either ORC or RARC. The investigators will focus upon measures of&#xD;
      functional recovery and the return to normal activities.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days at home within 90 days of the surgery</measure>
    <time_frame>90 days post surgery</time_frame>
    <description>To compare the number of days alive and out of hospital within 90 days from surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difficulties due to health conditions measured using WHODAS version 2.0</measure>
    <time_frame>12 months post surgery</time_frame>
    <description>To assess recovery and complications and the return to normal activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life measured using EQ-5D-5L Health Questionnaire and EORTC QLQ-C30 version 3.</measure>
    <time_frame>12 months post surgery</time_frame>
    <description>To assess recovery and complications and the return to normal activities.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">339</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>iRARC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intracorporeal Robot Assisted Radical Cystectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open Radical Cystectomy (ORC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Open Radical Cystectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intracorporeal Robot Assisted Radical Cystectomy</intervention_name>
    <description>Intracorporeal robot assisted radical cystoprostatectomy or anterior exenteration</description>
    <arm_group_label>iRARC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Open Radical Cystectomy</intervention_name>
    <description>Removal of bladder and adjacent organs</description>
    <arm_group_label>Open Radical Cystectomy (ORC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must be over 18 years of age.&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Histopathological confirmation of bladder cancer (UCC, SCC, adenocarcinoma or rare&#xD;
             variant)&#xD;
&#xD;
          -  CIS or stage pTa or pT1 or ≥pT2 or mobile bladder mass on bimanual examination under&#xD;
             anaesthesia (see Section 22: Definitions for TNM definitions)&#xD;
&#xD;
          -  Node status ≤ N1 on imaging criteria or PET -ve outside pelvis&#xD;
&#xD;
          -  ECOG grade 0, 1, 2 or 3&#xD;
&#xD;
          -  Able to give informed written consent to participate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwilling to undergo cystectomy.&#xD;
&#xD;
          -  Previous abdominal surgery rendering them unsuitable for either iRARC or ORC.&#xD;
&#xD;
          -  Patients with upper urinary tract disease&#xD;
&#xD;
          -  Concomitant disease that would render the patient unsuitable for the trial&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Previous radiotherapy for bladder cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Kelly</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College, London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Catto</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College, London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Bristol NHS Trust</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James' University Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Berkshire Hospital</name>
      <address>
        <city>Reading</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals NHS Foundation Trust</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lister Hospital</name>
      <address>
        <city>Stevenage</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 2, 2017</study_first_submitted>
  <study_first_submitted_qc>February 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2017</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

